X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1524) 1524
Publication (101) 101
Newsletter (78) 78
Book Review (39) 39
Book Chapter (6) 6
Magazine Article (4) 4
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
paroxetine (1090) 1090
humans (1017) 1017
male (748) 748
pharmacology & pharmacy (638) 638
female (592) 592
psychiatry (518) 518
adult (479) 479
fluoxetine (386) 386
index medicus (378) 378
middle aged (348) 348
antidepressants (327) 327
neurosciences (326) 326
animals (319) 319
pharmacokinetics (269) 269
serotonin (259) 259
depression (256) 256
paroxetine - pharmacokinetics (240) 240
drug interactions (234) 234
aged (229) 229
serotonin uptake inhibitors - therapeutic use (222) 222
paroxetine - pharmacology (220) 220
paroxetine - therapeutic use (209) 209
sertraline (207) 207
serotonin uptake inhibitors - pharmacology (201) 201
serotonin reuptake inhibitors (199) 199
rats (193) 193
serotonin uptake inhibitors - pharmacokinetics (189) 189
clinical neurology (182) 182
double-blind (179) 179
depressive disorder - drug therapy (175) 175
serotonin uptake inhibitors - adverse effects (174) 174
dose-response relationship, drug (166) 166
paroxetine - adverse effects (164) 164
fluvoxamine (161) 161
adolescent (145) 145
major depression (145) 145
treatment outcome (138) 138
citalopram (135) 135
metabolism (131) 131
drugs (126) 126
efficacy (126) 126
antidepressive agents - therapeutic use (122) 122
research (120) 120
double-blind method (119) 119
paroxetine - administration & dosage (114) 114
pharmacology (113) 113
brain - metabolism (112) 112
depressive disorder, major - drug therapy (112) 112
paroxetine - blood (107) 107
serotonin uptake inhibitors (107) 107
major depressive disorder (106) 106
serotonin - metabolism (104) 104
analysis (98) 98
serotonin transporter (94) 94
serotonin uptake inhibitors - administration & dosage (93) 93
drug therapy (91) 91
depression, mental (90) 90
antidepressive agents, second-generation - therapeutic use (89) 89
in-vitro (89) 89
cytochrome p-450 (88) 88
antidepressant (87) 87
serotonin plasma membrane transport proteins (87) 87
brain (86) 86
cyp2d6 (85) 85
rats, sprague-dawley (84) 84
venlafaxine (84) 84
antidepressive agents - pharmacology (82) 82
drug therapy, combination (81) 81
time factors (81) 81
antidepressive agents - adverse effects (78) 78
antidepressive agents - pharmacokinetics (78) 78
antidepressive agents, second-generation - adverse effects (77) 77
brain - drug effects (77) 77
h-3 paroxetine binding (77) 77
psychiatric status rating scales (75) 75
cytochrome p-450 cyp2d6 - metabolism (74) 74
depression - drug therapy (73) 73
young adult (73) 73
membrane transport proteins (72) 72
pharmacology/toxicology (72) 72
placebo (71) 71
blood platelets - metabolism (70) 70
health aspects (70) 70
mice (70) 70
depressive disorder - psychology (69) 69
fluoxetine - pharmacology (69) 69
care and treatment (68) 68
medicine & public health (68) 68
nerve tissue proteins (68) 68
serotonin uptake inhibitors - blood (68) 68
antidepressive agents, second-generation - pharmacokinetics (66) 66
cytochrome p-450 cyp2d6 inhibitors (66) 66
genotype (66) 66
imipramine (66) 66
rat-brain (66) 66
drug administration schedule (65) 65
paroxetine - metabolism (64) 64
ssri (64) 64
area under curve (63) 63
metabolites (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1574) 1574
German (10) 10
French (6) 6
Spanish (6) 6
Japanese (4) 4
Dutch (3) 3
Norwegian (2) 2
Chinese (1) 1
Danish (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Medicinal Chemistry, ISSN 0929-8673, 04/2012, Volume 19, Issue 12, pp. 1846 - 1863
New-generation antidepressants are a heterogeneous class of drugs used in the treatment of depression and related disorders. This review deals with the first... 
Paroxetine | Antidepressants | Fluoxetine | Pharmacological properties | Selective serotonin reuptake inhibitors (SSRIs) | Therapeutic drug monitoring (TDM) | Vilazodone | Fluvoxamine | Sertraline | Chemical-clinical correlations | Citalopram | ELECTRON-CAPTURE DETECTION | POSTTRAUMATIC-STRESS-DISORDER | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | fluvoxamine | TANDEM MASS-SPECTROMETRY | pharmacological properties | OBSESSIVE-COMPULSIVE DISORDER | PERFORMANCE LIQUID-CHROMATOGRAPHY | chemical-clinical correlations | therapeutic drug monitoring (TDM) | fluoxetine | paroxetine | selective serotonin reuptake inhibitors (SSRIs) | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | PLACEBO-CONTROLLED TRIAL | NEW-GENERATION ANTIDEPRESSANTS | citalopram | TRANSPORTER BINDING PROFILE | vilazodone | sertraline | SOLID-PHASE EXTRACTION | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Fluoxetine - pharmacokinetics | Humans | Citalopram - adverse effects | Depressive Disorder - drug therapy | Paroxetine - therapeutic use | Sertraline - adverse effects | Paroxetine - adverse effects | Benzofurans - pharmacokinetics | Sertraline - pharmacokinetics | Vilazodone Hydrochloride | Sertraline - therapeutic use | Fluoxetine - therapeutic use | Piperazines - pharmacokinetics | Fluoxetine - adverse effects | Fluvoxamine - therapeutic use | Benzofurans - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Fluvoxamine - pharmacokinetics | Serotonin Uptake Inhibitors - adverse effects | Piperazines - therapeutic use | Benzofurans - adverse effects | Depressive Disorder - metabolism | Fluvoxamine - adverse effects | Piperazines - adverse effects | Indoles - adverse effects | Citalopram - pharmacokinetics | Citalopram - therapeutic use | Indoles - pharmacokinetics | Indoles - therapeutic use | Drug Monitoring
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2003, Volume 95, Issue 23, pp. 1758 - 1764
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | BREAST-CANCER | MAJOR METABOLITES | ONCOLOGY | 4-HYDROXYLATION | RANDOMIZED CONTROLLED-TRIAL | HUMAN LIVER-MICROSOMES | CYP2D6 ACTIVITY | HOT FLASHES | CYTOCHROME-P450 2D6 | VENLAFAXINE | Cytochrome P-450 CYP2D6 Inhibitors | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Prospective Studies | Cytochrome P-450 Enzyme Inhibitors | Selective Estrogen Receptor Modulators - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - blood | Cytochrome P-450 CYP3A | Humans | Microsomes, Liver - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - pharmacokinetics | Paroxetine - administration & dosage | Paroxetine - blood | Breast Neoplasms - enzymology | Adult | Female | Serotonin Uptake Inhibitors - blood | Chemotherapy, Adjuvant | Antineoplastic Agents, Hormonal - administration & dosage | Enzyme Inhibitors - pharmacology | Tamoxifen - blood | Selective Estrogen Receptor Modulators - administration & dosage | Treatment Outcome | Tamoxifen - pharmacokinetics | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Selective Estrogen Receptor Modulators - blood | Serotonin Uptake Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Aged | Paroxetine | Evaluation | Serotonin uptake inhibitors | Tamoxifen
Journal Article
PHARMACOGENETICS AND GENOMICS, ISSN 1744-6872, 09/2016, Volume 26, Issue 9, pp. 403 - 413
Objective Although the reduced function of the cytochrome P450 2D6*10 (CYP2D6*10) allele is common among Asian populations, existing evidence does not support... 
ALLELE | ACTIVITY SCORE | polymorphisms | dose requirement | population pharmacokinetics | IMPACT | paroxetine | MECHANISM-BASED INHIBITION | CYP2D6 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENES | GENETICS & HEREDITY | PHARMACOLOGY & PHARMACY | PLASMA-CONCENTRATION
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2015, Volume 55, Issue 6, pp. 671 - 679
Journal Article
Journal of Neural Transmission, ISSN 0300-9564, 3/2017, Volume 124, Issue 3, pp. 387 - 396
Pre-clinical and clinical studies indicated that a blockade of the NMDA receptor complex creates new opportunities for the treatment of affective disorders,... 
Neurology | Neurosciences | Traxoprodil | Forced swim test | Pharmacokinetic study | Medicine & Public Health | Antidepressants | NMDA receptor ligand | Mice | Pharmacology/Toxicology | Psychiatry | TAIL SUSPENSION TEST | INVOLVEMENT | RATS | D-ASPARTATE ANTAGONIST | ZINC SUPPLEMENTATION | NEUROSCIENCES | CLINICAL NEUROLOGY | AMPA RECEPTORS | CP-101,606 | DRUGS | MAJOR DEPRESSIVE DISORDER | Paroxetine - pharmacokinetics | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Excitatory Amino Acid Antagonists - pharmacokinetics | Motor Activity - drug effects | Depressive Disorder - drug therapy | Male | Chromatography, High Pressure Liquid | Brain - metabolism | Desipramine - pharmacology | Drug Interactions | Piperidines - pharmacology | Piperidines - pharmacokinetics | Antidepressive Agents - pharmacology | Cyclopropanes - pharmacokinetics | Cyclopropanes - pharmacology | Disease Models, Animal | Bupropion - pharmacokinetics | Injections, Intraperitoneal | Excitatory Amino Acid Antagonists - pharmacology | Depressive Disorder - metabolism | Brain - drug effects | Desipramine - pharmacokinetics | Animals | Analysis of Variance | Bupropion - pharmacology | Antidepressive Agents - pharmacokinetics | Paroxetine - pharmacology | Physiological aspects | Paroxetine | Depression, Mental | Index Medicus | Psychiatry and Preclinical Psychiatric Studies - Original
Journal Article
Journal Article
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 05/2004, Volume 161, Issue 5, pp. 826 - 835
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2016, Volume 91, Issue 7, pp. 897 - 907
Abstract Antidepressants are commonly prescribed medications in the United States, and there is increasing interest in individualizing treatment selection for... 
Internal Medicine | CLINICAL IMPROVEMENT | CYP2C19 GENOTYPES | SEROTONIN REUPTAKE INHIBITORS | GENETIC-VARIATION | MEDICINE, GENERAL & INTERNAL | PLASMA-CONCENTRATIONS | CYTOCHROME-P450 2D6 GENOTYPE | DOSE-RESPONSE RELATIONSHIP | TRANSPORTER OCCUPANCY | MAJOR DEPRESSIVE DISORDER | DRUG CONCENTRATION | Paroxetine - pharmacokinetics | Antidepressive Agents, Second-Generation - adverse effects | Antidepressive Agents, Second-Generation - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors - therapeutic use | Fluoxetine - pharmacokinetics | Precision Medicine - standards | Humans | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Antidepressive Agents, Second-Generation - therapeutic use | Venlafaxine Hydrochloride - adverse effects | Paroxetine - adverse effects | Fluoxetine - therapeutic use | Fluoxetine - adverse effects | Pharmacogenetics - standards | Depressive Disorder, Major - drug therapy | Cytochrome P-450 CYP2D6 - genetics | Pharmacogenetics - methods | Prescription Drugs - standards | Cytochrome P-450 Enzyme Inhibitors - pharmacokinetics | Depressive Disorder, Major - genetics | Venlafaxine Hydrochloride - pharmacokinetics | Precision Medicine - methods | Practice Guidelines as Topic | Genetic variation | Patient outcomes | Dosage and administration | Genetic aspects | Research | Drug therapy | Genetic screening | Major depressive disorder | Antidepressants, Tricyclic | Drugs | Prescription writing | Drug approval
Journal Article
FARMACIA, ISSN 0014-8237, 07/2019, Volume 67, Issue 4, pp. 616 - 620
Carvedilol is one of the most used cardiovascular drugs, highly metabolized by CYP450 2D6, 1A2, 2C9. Fluvoxamine, an antidepressant agent, is a moderate/potent... 
CITALOPRAM | inhibition | NEBIVOLOL | cytochrome P450 | FLUOXETINE | ZOLPIDEM | METABOLISM | CYP2D6 | BUPROPION | Carvedilol | PAROXETINE | PHARMACOLOGY & PHARMACY | STEADY-STATE
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 1/2011, Volume 67, Issue 1, pp. 63 - 71
The main metabolic pathways of oxycodone, a potent opioid analgetic, are N-demethylation (CYP3A4) to inactive noroxycodone and O-demethylation (CYP2D6) to... 
Paroxetine | Pharmacodynamics | Biomedicine | Ketoconazole | Oxycodone | Drug interactions | Pharmacology/Toxicology | Pharmacokinetics | MORPHINE | CONTROLLED-RELEASE OXYCODONE | FLUOXETINE | N-DEALKYLATION | SEROTONIN REUPTAKE INHIBITOR | DOUBLE-BLIND